KaydedilenlerDerginizi ekleyin

Dergiler / Acta Medica / 2022 / Cilt: 53 - Sayı: 2

Can Syndecan-1 Be Used As A Biomarker In Alzheimer’s Disease?

Rana Tuna DOĞRUL
Cagatay ÇAVUŞOĞLU
Gozde Sengul AYÇİÇEK
Cemile ÖZSÜREKÇİ
Hatice ÇALIŞKAN
Hacer DOĞAN VARAN
Zeliha GÜNNÜR DİKMEN
Mustafa CANKURTARAN
Burcu Balam DOĞU
Sayfa
166–172
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Results: When patients were grouped as control, MCI and AD, significant decreases were observed in Katz daily living activity (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Syndecan-1 (SDC-1) is a member of the syndecan family, which includes heparan sulfate proteoglycans.
📊
Temel Bulgular & Veri:SDC-1 is important for cell-cell and cell-matrix interactions.
💡
Sonuç & Katkı:Results: When patients were grouped as control, MCI and AD, significant decreases were observed in Katz daily living activity (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background: Syndecan-1 (SDC-1) is a member of the syndecan family, which includes heparan sulfate proteoglycans. SDC-1 is important for cell-cell and cell-matrix interactions. The aim of this study is to examine the relationship between serum SDC-1 levels and mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Methods: Eighty-two patients aged 65 years and over were included in the study. The Mini-Mental State Examination (MMSE) was used to evaluate the cognitive functions of the patients. Comprehensive geriatric assessment components were administered to the patients. Serum SDC- 1 levels were measured with an enzyme-linked immunosorbent assay kit. Results: When patients were grouped as control, MCI and AD, significant decreases were observed in Katz daily living activity (p

🔖

Bu Makaleye Atıf Yap

DOĞRUL, R. T., ÇAVUŞOĞLU, C., AYÇİÇEK, G. S., ÖZSÜREKÇİ, C., ÇALIŞKAN, H., VARAN, H. D., DİKMEN, Z. G., CANKURTARAN, M., DOĞU, B. B. (2022). Can Syndecan-1 Be Used As A Biomarker In Alzheimer’s Disease?. Acta Medica, Cilt: 53 - Sayı: 2, 166–172. https://ajindex.com/articles/427525

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Vagnucci Jr, A.H. and W.W. Li, Alzheimer’s disease and angiogenesis. The Lancet, 2003. 361(9357): p. 605-608
  2. Morris, G.P., I.A. Clark, and B. Vissel, Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta neuropathologica communications, 2014. 2(1): p. 1-21
  3. Liu, C.-C., et al., Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer’s disease. Science translational medicine, 2016. 8(332): p. 332ra44-332ra44
  4. Bruinsma, I.B., et al., Sulfation of heparan sulfate associated with amyloid-β plaques in patients with Alzheimer’s disease. Acta neuropathologica, 2010. 119(2): p. 211-220
  5. Nguyen, K. and D.L. Rabenstein, Interaction of the heparinbinding consensus sequence of β-amyloid peptides with heparin and heparin-derived oligosaccharides. The Journal of Physical Chemistry B, 2016. 120(9): p. 2187- 2197
  6. Palaiologou, M., I. Delladetsima, and D. Tiniakos, CD138 (syndecan-1) expression in health and disease. 2014
  7. Petersen, R.C., et al., Mild cognitive impairment: clinical characterization and outcome. Archives of neurology, 1999. 56(3): p. 303-308
  8. McKhann, G., et al., Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 1984. 34(7): p. 939-939
  9. American Psychiatric Association, A. and A.P. Association, Diagnostic and statistical manual of mental disorders: DSM-5. 2013, Washington, DC: American psychiatric association
  10. Reisberg, B., Functional assessment staging (FAST). Psychopharmacol Bull, 1988. 24: p. 653-659
  11. Katz, S., et al., Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. Jama, 1963. 185(12): p. 914-919
  12. Lawton, M.P. and E.M. Brody, Assessment of older people: self-maintaining and instrumental activities of daily living. The gerontologist, 1969. 9(3_Part_1): p. 179-186
  13. Yesavage, J.A., Geriatric depression scale. Psychopharmacol Bull, 1988. 24(4): p. 709-711
  14. Rubenstein, L.Z., et al., Screening for undernutrition in geriatric practice: developing the short-form mininutritional assessment (MNA-SF). The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2001. 56(6): p. M366-M372
  15. Folstein, M.F., S.E. Folstein, and P.R. McHugh, “Mini-mental state”: a practical meth